Navigation Links
Pharmaxis Establishes Named Patient Program for Bronchitol
Date:6/16/2008

SYDNEY, Australia, June 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced the appointment of IDIS Limited to manage and provide eligible patients worldwide with access to Bronchitol through a Named Patient Program.

The program will allow patients who are unable to participate in current Pharmaxis clinical trials but who are considered by their physician to be suffering from a clinical condition for which no satisfactory authorised alternative exists, to receive access to Bronchitol on a named patient basis.

The program will establish a common approach to the use and distribution of Bronchitol and the eligibility of patients.

"IDIS is a partner of choice for major global pharmaceutical companies in providing ethical named patient access to medicines in countries where the product is yet to be authorised," said Pharmaxis CEO Alan Robertson.

"Bronchitol will be made available to people with a chronically or seriously debilitating, or life threatening condition who cannot be treated satisfactorily by an authorized medicine.

"IDIS manages Named Patient Programs in over 100 countries, and is recognised for its rigorous capture of pharmacovigilance information and quality doctor education programs.

"We are pleased to be able to offer the option of Bronchitol to physicians with patients in urgent need," said Dr Robertson.

Bronchitol is in final clinical trials for the treatment of the chronic lung conditions cystic fibrosis and bronchiectasis. The U.S. Food and Drug Administration has granted Bronchitol fast track status and it is designated as an orphan drug in the U.S. and Europe.

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

CONTACT:

Alan Robertson

Chief Executive Officer

Tel: +61-2-9454-7200

Email: alan.robertson@pharmaxis.com.au

Further information on the Program is available from IDIS Limited:

Tel: +44-1932-824000

Email: gma@idispharma.com

Released through:

Australia:

Virginia Nicholls

Tel: +61-417-610-824

Email: virginia.nicholls@pharmaxis.com.au

United States:

Brandon Lewis

Trout Group

Tel: +1-646-378-2915

Email: blewis@troutgroup.com


'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaxis Long-Term Safety Study of Bronchitol Completes
2. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
3. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
4. Aspirin Named 8th World Wonder by Majority of Americans
5. American Board of Internal Medicine President Named to Alzheimers Study Group
6. New York Infection Prevention Expert Named Recipient of Carole DeMille Award
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, ... report , "Alzheimer Diagnostic Tests - Medical Devices ... Diagnostic Tests currently in pipeline stage. The ... with comparative analysis of the products at various ... involved in the pipeline product development. It also ...
(Date:2/8/2016)... 2016 CBG Technologies, a U.S. company, ... Recycling Systems, specifically designed for precision parts cleaning. ... and existing vapor degreasers, parts washers and ultrasonic ... continuous recycling and recovers 100% of the solvent ... --> Precision parts manufacturers benefit from this ...
(Date:2/8/2016)... 2016 --> ... "Ablation Technologies Market by Product (Radiofrequency, Ultrasound, Irreversible Electroporation, ... Surgery, Ophthalmology, Gynecology) - Global Forecasts to 2020", published ... the forecast period of 2015 to 2020. The market ... CAGR of 10.5% from 2015 to 2020. ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... newly redesigned website, federallabs.org . The site houses a wealth of federal ... federal technologies through the process called technology transfer (T2). As a network of ...
(Date:2/8/2016)... ... ... has struggled to quit smoking, a man who has struggled with hair loss – Craig ... problems – and he did. Now Nabat, a serial entrepreneur featured as the October 2015 ... the world and better people's lives. His own experience with nicotine addiction led to the ...
(Date:2/8/2016)... Indianapolis, IN (PRWEB) , ... February 08, 2016 ... ... serving the Indianapolis, IN metro area, has selected the latest beneficiary of their ... nonprofit organization dedicated to preventing bullying in area schools. Donations are now being ...
(Date:2/8/2016)... ... 08, 2016 , ... Eating disorders and post-traumatic stress disorder ... and men with eating disorders report a history of trauma, research suggests that ... an eating disorder. , At the 2016 iaedp Symposium, the workshop, “What ...
(Date:2/8/2016)... ... February 08, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating ... Moles are derived from a cluster of melanin when exposed to sunlight. Although most ... create a lifetime of embarrassment. Historically, mole removal has involved a painful, ...
Breaking Medicine News(10 mins):